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Introduction: cannabis   continues to affect 
mental health. Its abuse is on rise globally. 
In Canada a rise by 30% in last ten years 
has been observed in high school students. 
Interrelationship of cannabis with psychosis 
and schizophrenia is a complex one. 
Cannabis is highly comorbid with psychosis, 
& related to functional disability and 
outcome. It poses several challenges in 
understanding causal relationship for 
comorbidity, underlying neurochemical basis 
and specifics of service development. 
Prevalence of Cannabis varies from 20 to 
50% early psychosis. Objective of this paper 
is to review available literature to identify 
challenges for newer targets of research and 
preventive measures. 
Method: Recent literature from electronic 
data base search identifies role and 
relationship of cannabis and psychosis.  
Results. Cannabis is a risk factor for both 
psychosis and schizophrenia. &  Appears to 
have causal relationship for early and later-
age psychosis.  Mood symptoms are also 
significant but less recognized. 
Understandings of the process and causes 
have significantly advanced with discovery 
of cannabinoid receptors and endogenous 
cannabinoids. It is   clear that cannabis 
increases brain vulnerability, causes poorer 
outcome and more side effects. Cannabis 
causes cognitive dysfunction that perhaps 
works as a common denominator for the 
risk-vulnerability. It appears to have 
independent genetic component related to 
disruption in neurotransmission affecting 
neuronal plasticity. Much less attention has 
been paid in developing services targeted 
towards harm reduction and developing 
therapeutics.  
Conclusion. Cannabis is potential risk factor 
for poorer outcome in psychosis. New 
biological and social service initiatives will 
add value to early psychosis programs 
Amresh Shrivastava, Department of Psychiatry, University of Western Ontario, London, Canada 
  
  
INSERT YOUR 
ORGANIZATION’S 
 LOGO HERE 
Explanation for close relationship between 
Psychosis &  cannabis is still unclear.  
Available evidence for ‘causal relationship’ suggests 
only possibilities 
 There is a very strong epidemiological evidence for 
correlation/comorbidity. 
 Cannabis is a risk factor for psychosis, for a  
variety of syndromes at later age. 
 There seems to be no reliable biological 
explanation as to why exposure to cannabis should 
precipitate psychosis. 
 THC causes brain effects and influences mental 
condition by causing abnormal transmission with 
dopamine   
 There are regional changes in prefrontal cortex as 
well as sub-cortical regions most of the behavioural  
effects are due to modulation of CB receptors. 
 Cognitive impairment due to cannabis remains 
uncertain and unexplained 
  Predominant questions  
& Limitations  of available research data  
 Is cannabis involved in memory impairment? 
  Do Cognitive effects (arising from Cannabis) form a ‘risk –factor’ for psychosis? 
 What are the biochemical correlates of these cognitive changes?  
 Will cognitive enhancement reduce the risk for psychosis in abusers?  Will it be 
possible to develop such cognitive enhancers?  
 Limited data-still needs more political push  &  more  group initiatives in 
research of Cannabis and Mental Health.  
 However there are sufficient pointers to suggest the possibilities and need for 
more aggressive research. 
. 
What do we know with ‘Limited Evidence’? 
 The brain changes seen by imaging 
 Influence on brain development during adolescence  
 Nature of most toxic metabolite which is psychosis-genic. 
 Role of CB receptors in schizophrenia and psychosis 
 The pathogenesis of risk. 
 The ‘Cannabis Phenotype of Psychosis’ 
 Validity of Diagnosis : ‘Cannabis-Induced-Psychosis’ Vs. ‘Cannabis-
Toxic-Psychotic State’ 
 Adolescent mental health & Cannabissuggest long-term deleterious 
outcomes in cognition, depressive symptoms, schizophrenia 
 neurodevelopmental effect,  
 predisposing genetic and/or environmental factors 
 Gender specific differences.  
 how cannabinoids influence neurodevelopment 
  development of therapeutic tools for a variety of neuropsychiatric disorders 
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Adolescence Drug abuse Mood problems 
Comorbidity 
Psychosis 
40% to 70% 
of 
adolescent
s -  at least 
one drug or 
alcohol 
problem. 
With respect to sequencing, 
mood and other psychiatric 
disorders occur after the 
onset of drug-related 
problems. .This may not 
hold true for schizophrenia, 
however, which does 
frequently occur in 
adolescents., however the 
evidence is changing 
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Cannabis 
Cognition 
Early age use , Polydrug abuse, Personality type-
nonspecific-predisposed social anxiety and dysphoria, 
good evidence for comorbidity ASPD-83% Enhance 
vulnerability  { with OD 29.6,  Life Time Prevalence  for 
cannabis dependence was 14.7% } 
Cannon M, Clarke MC. 
Risk for schizophrenia--broadening the concepts, pushing back the 
boundaries. Schizophr Res. 2005 Nov 1;79(1):5-13. 
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Adjusted odds ratio for any psychosis outcome according to ever use verses ‘Frequent use’ 
of Cannabis in individual studies at 95% CI 
Theresa et al , Lancet, 2007 
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What happens  What causes 
Knowledge of Neurochemical correlates &  exact neuronal mechanism of cognitive 
dysfunction continues to be a major limitation in understanding the deficit and 
developing therapeutics.   
How  does the cognitive dysfunction arise? 
Cannabis 
Psychosis Cognition 
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Most users don’t develop Psychosis;  
95% of  18 year; 90% of 15 years old; Did not develop at age 26 – Capsi et al 
 Neurobiology of cognition is one of the most challenging in research.  
Two main 
questions 
Why Cognition is 
significant to 
psychosis? 
What impact can 
cannabis cause 
on Cognition? 
E-CB - endo 
cannabinoid
s provides 
Explanation 
For 
Cognitive 
deficits  
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detectable schizophrenia prodromes 
cognitive 
ability, 
subjective 
reports of 
impairment 
and coping.  
Risk for transition to full-blown 
psychotic disorder 
,  
size of 
psychosis 
"load," 
comorbid 
distress and 
depression, 
cannabis use 
Toward a world consensus on prevention of schizophrenia. 
Van Os J, Delespaul P.; Dialogues Clin Neurosci. 2005;7(1):53-67. 
heavy cannabis use in adolescence.  
Extensive areas of the 
cortex (especially in the 
frontal and temporal cortex)  
Subcortex (Amygdala, 
Hippocampus & Insular 
cortex) Basal regions 
(striatum)  
These alterations are 
associated with abnormal 
patterns of activation during  
cognitive memory tasks,  
inhibition & decision-making  
Rev Neurol. 2007 Apr 1-15;44(7):432-9. 
Structural 
abnormalities 
generally have not 
been identified 
with chronic use. 
Regular users 
demonstrate 
reciprocal 
changes in brain 
activity globally 
and in cerebellar 
and frontal 
regions.  
Abstinence 
results in 
decreases, and 
administration 
results in 
increases 
correlating with 
subjective 
intoxication.  
Findings correlate 
partially with 
neuropsychologic
al data, 
J Neuropsychiatry Clin Neurosci. 2006 
Summer;18(3):318-32 
Brain neuroimaging in  
cannabis use indicates   
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• Cannabinoids & 
Neurogenesis 
• Cannabis & 
Neuro-protection 
• Cannabinoids & 
immunity/ Glioma 
• Cannabinoids & 
Neurodegeneration 
• Cannabis & 
Cognition 
Huntington's 
disease 
 Parkinson's 
disease Schizophrenia Tremors 
Potential therapeutic targets 
currently under investigation 
cannabinoid Agonists and antagonists :  interrupt -     
synthesis, uptake or metabolism of the endocannabinoids. 15/03/2008 1 Amresh.Shrivastava        
Cannabis-
Related-
Psychosis 
What are 
the 
factors? 
What is 
the 
process? 
How to 
change? 
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What 
therapeutics 
can be applied? 
What brain 
mechanisms 
are the 
processes? 
Is Cognition 
the factor? 
Settle the issue of 
Cannabis induced  
diagnosis  
To prove that Cannabis increases brain vulnerability 
by itself , various evidences are required 
It changes cognition in 
nature and degree 
That there is a 
genetic basis for 
cannabis induced 
Cognitive changes 
That there are 
biochemical 
correlates which 
can explain the 
change 
Cognitive changes are 
not dependent upon 
genetic liability of 
psychosis 
That these 
changes are 
supported by 
imaging studies 
That 
epidemiological & 
Clinical studies can 
conform 
diagnosable 
phenotypes 
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